The estimated Net Worth of Gaurav Shah is at least $20 Milion dollars as of 16 August 2024. Gaurav Shah owns over 9,650 units of Rocket Pharmaceuticals Inc stock worth over $13,671,514 and over the last 7 years he sold RCKT stock worth over $2,463,766. In addition, he makes $3,883,650 as President, Chief Executive Officer oraz Director at Rocket Pharmaceuticals Inc.
Gaurav has made over 15 trades of the Rocket Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 9,650 units of RCKT stock worth $178,525 on 16 August 2024.
The largest trade he's ever made was exercising 290,000 units of Rocket Pharmaceuticals Inc stock on 25 February 2020 worth over $124,700. On average, Gaurav trades about 31,506 units every 91 days since 2018. As of 16 August 2024 he still owns at least 718,419 units of Rocket Pharmaceuticals Inc stock.
You can see the complete history of Gaurav Shah stock trades at the bottom of the page.
Dr. Gaurav Shah M.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Shah has served as our President and Chief Executive Officer and as one of our directors since January 2018. Dr. Shah was appointed Chief Executive Officer of Private Rocket in September 2015. Prior to joining Private Rocket, from 2011-2015, Dr. Shah held various leadership positions at Novartis including Global Program Head for CART-19, Global Clinical Program Head for CTL-019 and Biosimilars, and Global Clinical Leader for Afinitor. Prior to Novartis, he spent three years at Eli Lilly and Company as Medical Director overseeing clinical development of numerous programs including olaratumab. During his industry tenure, he has participated in several drug development programs resulting in successful regulatory approvals, such as CTL-019 in pediatric ALL, the first cell and gene therapy approved in the U.S., and successful commercial launches. Prior to joining industry, Dr. Shah was Assistant Professor of Medicine/Oncology at Columbia University. He holds a B.A. in Behavioral Neuroscience from Harvard University and an MD from Columbia University. Dr. Shah completed his internal medicine residency at Brigham and Women’s Hospital/Harvard Medical School and completed his hematology/oncology fellowship training at the Memorial-Sloan Kettering Cancer Center. Shah is qualified to sit on our Board due to his role as Chief Executive Officer of the Company and his significant leadership and management experience in the biopharmaceutical industry.
As the President, Chief Executive Officer oraz Director of Rocket Pharmaceuticals Inc, the total compensation of Gaurav Shah at Rocket Pharmaceuticals Inc is $3,883,650. There are no executives at Rocket Pharmaceuticals Inc getting paid more.
Gaurav Shah is 45, he's been the President, Chief Executive Officer oraz Director of Rocket Pharmaceuticals Inc since 2018. There are 10 older and 6 younger executives at Rocket Pharmaceuticals Inc. The oldest executive at Rocket Pharmaceuticals Inc is Pedro Granadillo, 73, who is the Independent Director.
Gaurav's mailing address filed with the SEC is C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY, NJ, 08512.
Over the last 7 years, insiders at Rocket Pharmaceuticals Inc have traded over $45,364,690 worth of Rocket Pharmaceuticals Inc stock and bought 2,407,332 units worth $48,979,646 . The most active insiders traders include Investments, Lpwong Roderic..., Mikael Dolsten oraz Investments, Lpwong Roderic.... On average, Rocket Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $1,269,815. The most recent stock trade was executed by John Militello on 16 August 2024, trading 1,064 units of RCKT stock currently worth $19,684.
rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.
Rocket Pharmaceuticals Inc executives and other stock owners filed with the SEC include: